Director Eric S. Fain filed a Form 4 with the SEC on November 9, 2026, disclosing a purchase of 20,000 shares of Orchestra BioMed Holdings, Inc. common stock at $5.00 per share through an underwritten public offering.
Key Highlights
- Transaction date: November 9, 2026, the date of earliest transaction as stated in the filing.
- Shares purchased: 20,000 shares of Common Stock, par value $0.0001 per share, acquired (code P).
- Purchase price: $5.00 per share, described as the public offering price in an underwritten public offering of the issuer.
- Resulting ownership: 119,630 shares beneficially owned following the transaction, held indirectly by the Fain Living Trust.
- Reporting person's role: Eric S. Fain is identified as a Director of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO).
- Filing type: Filed by one reporting person; no derivative securities transactions were reported.
Director Fain Acquires Orchestra BioMed Shares in Public Offering
According to the Form 4 filing, Eric S. Fain, a director of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), acquired 20,000 shares of the company's Common Stock, par value $0.0001 per share, on November 9, 2026. The filing states that "these shares were purchased in an underwritten public offering of the Issuer at the public offering price of $5.00 per share." The transaction is recorded with transaction code P, indicating an open-market or offering purchase.
Following the reported transaction, the filing discloses that Fain beneficially owns 119,630 shares in total, held indirectly through the Fain Living Trust. No shares are reported as directly owned, and no derivative securities transactions appear in Table II of the filing. The form was signed by Andrew Taylor as Attorney-in-Fact on November 9, 2026.
The filing was submitted individually, as indicated by the "Form filed by One Reporting Person" designation. No amendment date is listed, indicating this is an original filing rather than a revision to a previously submitted form.
What Was Disclosed
The filing reports a single acquisition of 20,000 shares of Orchestra BioMed Holdings common stock by Director Eric S. Fain at $5.00 per share through an underwritten public offering on November 9, 2026, bringing his indirect beneficial ownership to 119,630 shares held via the Fain Living Trust.




Please wait processing your request...